

A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the progression of calcific aortic valve stenosis [Lp(a)FRONTIERS CAVS]

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- men and women between the ages of 50 and 79 - diagnosis of mild or moderate calcific aortic valve stenosis

Exclusion Criteria:

- ejection fraction (EF) less than 55% - severe aortic or mitral valve stenosis - uncontrolled hypertension - history of cancer - women who are pregnant or breast feeding - unable to have an echocardiogram or CT scan

Conditions & Interventions

Conditions:

Heart & Vascular

Keywords:

Clinics and Surgery Center (CSC), elevated Lp(a), Aortic Stenosis

More Information

Description: The purpose of the study is to assess if the study treatment, pelacarsen, taken by people with mild or moderate CAVS and elevated lipoprotein(a) can safely help slow the progression of calcific aortic valve stenosis (CAVS). Pelacarsen is a treatment being tested that acts on a particle called Lp(a), which if elevated, may play a role in CAVS.

Study Contact: Michelle Pitt - henni032@umn.edu

Principal Investigator: Daniel Duprez

Phase: PHASE2

IRB

Number: STUDY00022219

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.